Preprint Case Report Version 1 This version is not peer-reviewed

Brief Report: Rapid Clinical Recovery from Critical COVID-19 with Respiratory Failure in a Lung Transplant Patient Treated with Intravenous Vasoactive Intestinal Peptide

Version 1 : Received: 8 July 2020 / Approved: 9 July 2020 / Online: 9 July 2020 (07:54:22 CEST)
Version 2 : Received: 1 August 2020 / Approved: 2 August 2020 / Online: 2 August 2020 (18:16:20 CEST)

How to cite: Youssef, J.G.; Zahiruddin, F.; Al-Saadi, M.; Yau, S.; Goodarzi, A.; Huang, H.J.; Javitt, J.C. Brief Report: Rapid Clinical Recovery from Critical COVID-19 with Respiratory Failure in a Lung Transplant Patient Treated with Intravenous Vasoactive Intestinal Peptide . Preprints 2020, 2020070178 (doi: 10.20944/preprints202007.0178.v1). Youssef, J.G.; Zahiruddin, F.; Al-Saadi, M.; Yau, S.; Goodarzi, A.; Huang, H.J.; Javitt, J.C. Brief Report: Rapid Clinical Recovery from Critical COVID-19 with Respiratory Failure in a Lung Transplant Patient Treated with Intravenous Vasoactive Intestinal Peptide . Preprints 2020, 2020070178 (doi: 10.20944/preprints202007.0178.v1).

Abstract

RLF-100 (Aviptadil), a synthetic form of Vasoactive Intestinal Peptide (VIP) has been granted Fast Track Designation by the US FDA for the treatment of Critical COVID-19 with Respiratory Failure. We describe the clinical course of the first patient treated with this investigational medication in an open label manner -- a 54 year old patient suffering antibody-mediated rejection of his double lung transplant who contracted COVID-19 with respiratory failure refractory to all currently available therapies. He received three infusions of RLF-100 under an FDA-approved emergency use IND. Within 24 hours of the third infusion, substantial improvement in oxygen saturation and radiographic improvement in characteristic COVID-19 pneumonitis was noted. He was discharged from intensive care at that point and returned home at 1 week on room air.

Subject Areas

Aviptadil; Vasoactive Intestinal Peptide; VIP; SARS-CoV-2; COVID-19; Corona Virus; Acute Respiratory Distress Syndrome; ARDS; Acute Lung Injury; ALI; surfactant; Alveolar Type II; ATII

Comments (0)

We encourage comments and feedback from a broad range of readers. See criteria for comments and our diversity statement.

Leave a public comment
Send a private comment to the author(s)
Views 0
Downloads 0
Comments 0
Metrics 0


×
Alerts
Notify me about updates to this article or when a peer-reviewed version is published.